Biocon share price
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹332.45up ₹3.65 (1.11%)BSE ₹333.80
Share price at the NSE close on 27 Oct 2026. Previous close ₹328.80.
27 Oct: open ₹329.80, high ₹334.65, low ₹328.00
52-week range of traded prices to 27 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹54,179 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 109.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 60.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.15%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 30,40,82149.3% delivered
About Biocon
Biocon Limited is a Bengaluru-based biopharmaceutical company that makes biosimilars (close copies of biologic medicines whose patents have expired) and generic medicines for chronic conditions such as diabetes, cancer, obesity and immune diseases.1 It sells in North America, Europe and emerging markets including Latin America, the Middle East, North Africa and Asia.23 Through its subsidiary Syngene International, it also offers contract research, development and manufacturing.3
Its biosimilars include insulins and monoclonal antibodies (lab-made proteins that act on specific targets in the body) used in diabetes, cancer, immunology, eye disease and bone health.45 Its generics business, which began with a statin made by fermentation, makes active pharmaceutical ingredients (APIs, the active substance of a medicine), including statins and immunosuppressants, and finished generic medicines.36
It was incorporated in 1978 and listed on the stock exchanges in 2004.78 In 2022 it acquired the biosimilars business of Viatris.4 It then acquired the remaining shares of its biosimilars subsidiary Biocon Biologics, through share swaps and $400 million in cash paid to Mylan, and Biocon Biologics became wholly owned on 29 Jun 2026.910 It raised ₹45,000 million in Jun 2025 and ₹41,500 million in Jan 2026 through qualified institutions placements (sales of new shares to large institutional investors).11
At the end of Mar 2026, Biocon owned 52.4% of Syngene International, which is separately listed.124 Kiran Mazumdar-Shaw is Executive Chairperson, and Shreehas Tambe became Chief Executive Officer and Managing Director on 1 Apr 2026.13
Biocon key points
Results
- In the quarter to Jun 2026, consolidated revenue from operations grew 10% year on year, and EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹902 crore, a margin of 21%.14
- Biocon's net profit before one-off items was ₹145 crore in the quarter, up 245%, and interest cost fell 23% to ₹213 crore.15
- In the year to Mar 2026, Biocon's revenue from operations rose 11% to ₹169,270 million; EBITDA was ₹37,978 million, a 22% margin, up 25% like-to-like (excluding one-time lenalidomide sales and a business sold a year earlier) and down 13% as reported.161718
- Biocon's net profit attributable to shareholders for the year was ₹3,856 million, up 186% like-to-like and down 62% as reported, and net debt (debt after deducting cash) was 2.7 times EBITDA at the end of Mar 2026.192021
Market position
- In its annual report for the year to Mar 2026, the company described Kirsty, its biosimilar insulin aspart, as the first and only interchangeable rapid-acting biosimilar insulin approved in the US (one a pharmacy may substitute for the original).22
Business segments
- Biosimilars. 60% of segment revenue in the year to Mar 2026: ₹104,312 million, up 16% like-to-like. Quarter to Jun 2026 revenue rose 16% to ₹2,855 crore; EBITDA rose 10% to ₹728 crore, a 25% margin.2324
- Generics. 18% of segment revenue in the year to Mar 2026: ₹31,681 million, up 17% like-to-like. Quarter to Jun 2026 revenue rose 21% to ₹760 crore; EBITDA was ₹56 crore.2526
- Contract research and manufacturing (CRDMO, Syngene). 22% of segment revenue in the year to Mar 2026: ₹37,387 million, up 3%. Quarter to Jun 2026 revenue fell 16% to ₹736 crore on lower offtake (volumes taken) from a key biologics client.2728
Plants and capacity
- Generic APIs are made in Bengaluru, Hyderabad and Visakhapatnam, and tablets and capsules in Bengaluru and Cranbury, New Jersey; biosimilars in Bengaluru and Malaysia. Syngene has a biologics plant in Baltimore, US.2930
- Biocon's annual capacity is 3,500+ kilolitres (KL) of generic API reactor volume, 2.5 billion tablets and capsules and 10+ million injectables, plus 300 KL of biosimilar drug substance (bulk active ingredient) and 100+ million drug product units (finished doses).31
- In the quarter to Jun 2026, the European Medicines Agency approved a second insulin drug product line in Malaysia, which the company says doubles that capacity, and supplies have started.3233
Customers and partners
- No single customer accounted for more than 10% of group revenue in the year to Mar 2026.34
- Syngene has worked with over 400 customers and in the year to Mar 2026 extended its Bristol Myers Squibb partnership through 2035, widening its scope.3536
- The generics business served over 500 customers in more than 60 countries in the year to Mar 2026.37
Research and development
- Biocon's R&D spending was 8% of revenue excluding Syngene in the year to Mar 2026; biosimilars made 101 regulatory filings and won 79 approvals, and generics filed 44 formulation dossiers and won 41 approvals.3839
- In the year to Mar 2026 Biocon disclosed new biosimilar cancer assets: nivolumab, pembrolizumab and a subcutaneous (injected under the skin) form of trastuzumab.40
What the company expects
- On its earnings call of 6 Aug 2026, the company said it expects biosimilars growth to build through the year to Mar 2027, with an acceleration in the second half.41
- The company said it expects Syngene's revenue to fall by a single-digit percentage in rupees in the year to Mar 2027, with EBITDA margins back to the mid-20s, and a return to growth from the year to Mar 2028.4243
- The company said it aims for a new product launch in the US or Europe every year until the end of the decade.44
Recent events
- The European Medicines Agency's medicines committee recommended approving Pebrilzo, Biocon's biosimilar of the breast cancer drug pertuzumab, the first antibody biosimilar so recommended under its tailored approach (relying more on laboratory evidence). As of 21 Sep 2026, the European Commission's decision was pending.45
- A consortium of Biocon, Bahiafarma and Bionovis won 100% of the allocation for pertuzumab under Brazil's 10-year Productive Development Partnership (a public programme that moves a medicine's production into Brazil), with exclusive access to the public market, about 70% of Brazil's pertuzumab demand.46
- The US Food and Drug Administration approved Biocon's generic liraglutide (a copy of the weight-loss drug Saxenda), marking its entry into the US GLP-1 market (a class of diabetes and weight-loss medicines).4748
- S&P Global Ratings raised its credit rating (an assessment of ability to repay debt) on Biocon Biologics to BB+ from BB, with a stable outlook.49
Last updated
All 49 sources, each with its page
- 1. Exchange filing, 21 Sep 2026, page 3
- 2. Investor presentation, 6 Aug 2026, page 5
- 3. Annual report, 15 Jul 2026, page 427
- 4. Annual report, 15 Jul 2026, page 229
- 5. Annual report, 15 Jul 2026, page 232
- 6. Annual report, 15 Jul 2026, page 233
- 7. Annual report, 15 Jul 2026, page 427
- 8. Exchange filing, 28 Jan 2026, page 2
- 9. Annual report, 15 Jul 2026, page 191
- 10. Exchange filing, 29 Jun 2026, page 2
- 11. Annual report, 15 Jul 2026, page 191
- 12. Annual report, 15 Jul 2026, page 410
- 13. Annual report, 15 Jul 2026, page 188
- 14. Earnings call, 6 Aug 2026, page 6
- 15. Earnings call, 6 Aug 2026, page 6
- 16. Annual report, 15 Jul 2026, page 67
- 17. Annual report, 15 Jul 2026, page 413
- 18. Annual report, 15 Jul 2026, page 6
- 19. Annual report, 15 Jul 2026, page 67
- 20. Annual report, 15 Jul 2026, page 6
- 21. Annual report, 15 Jul 2026, page 32
- 22. Annual report, 15 Jul 2026, page 97
- 23. Annual report, 15 Jul 2026, page 6
- 24. Earnings call, 6 Aug 2026, page 6
- 25. Annual report, 15 Jul 2026, page 6
- 26. Earnings call, 6 Aug 2026, page 7
- 27. Annual report, 15 Jul 2026, page 6
- 28. Earnings call, 6 Aug 2026, page 7
- 29. Annual report, 15 Jul 2026, page 233
- 30. Annual report, 15 Jul 2026, page 80
- 31. Annual report, 15 Jul 2026, page 77
- 32. Earnings call, 6 Aug 2026, page 6
- 33. Investor presentation, 6 Aug 2026, page 9
- 34. Annual report, 15 Jul 2026, page 414
- 35. Annual report, 15 Jul 2026, page 238
- 36. Annual report, 15 Jul 2026, page 16
- 37. Annual report, 15 Jul 2026, page 234
- 38. Annual report, 15 Jul 2026, page 242
- 39. Annual report, 15 Jul 2026, page 97
- 40. Annual report, 15 Jul 2026, page 97
- 41. Earnings call, 6 Aug 2026, page 6
- 42. Earnings call, 6 Aug 2026, page 7
- 43. Investor presentation, 6 Aug 2026, page 13
- 44. Earnings call, 6 Aug 2026, page 17
- 45. Exchange filing, 21 Sep 2026, page 2
- 46. Exchange filing, 8 Sep 2026, page 2
- 47. Exchange filing, 24 Feb 2026, page 2
- 48. Annual report, 15 Jul 2026, page 236
- 49. Exchange filing, 28 Jan 2026, page 4
Results
Consolidated; ₹ crore.Biocon quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +9.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +28.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹4,336 Crdown 4.00%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹137 Crdown 31.12%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 3.2%
Revenue by quarter
Peak revenue ₹4,517 Cr, quarter to Mar 2026; lowest ₹3,590 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 1 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 |
| Net profit | 27 | 81 | 459 | 89 | 133 | −52 | 199 | 137 |
| Net margin | 0.8% | 2.1% | 10.4% | 2.3% | 3.1% | −1.2% | 4.4% | 3.2% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹16,927 Crup 10.91%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹369 Crdown 74.20%
- Net margin
- 2.2%
Revenue by year
Peak revenue ₹16,927 Cr, year to Mar 2026; lowest ₹3,922 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,922 | 4,130 | 5,514 | 6,367 | 7,106 | 8,184 | 11,174 | 14,756 | 15,262 | 16,927 |
| Net profit | 612 | 372 | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 369 |
| Net margin | 15.6% | 9.0% | 18.2% | 13.7% | 11.9% | 9.4% | 5.8% | 8.8% | 9.4% | 2.2% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- BiosimilarsBiosimilars, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹10,431 Crup 15.68%60.2%
- CRDMOCRDMO, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,739 Cr21.6%
- GenericsGenerics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,168 Crup 4.99%18.3%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history.Biocon PE ratio and valuation
Price to earnings
At or below today's level on 64% of 1,841 trading days over the last 10 years.
LowestHighest
Its median47.16Industry median28.32
Price to book
At or below today's level on 3% of 1,805 trading days since Oct 2018.
LowestHighest
Its median4.49Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 48% of 2,473 trading days over the last 10 years.
LowestHighest
Its median0.15%Industry median0.50%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +5.8% | −71.8% | +274.7% | 0.1% |
| 3 years | +20.6% | −14.9% | +41.5% | 0.2% |
| 5 years | −2.2% | −17.4% | +18.0% | 0.3% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2026.
Mutual fund holdings
217 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 99 of the 131 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.All 217 funds holding Biocon
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 68
- CutCut. Funds that held fewer shares than at the end of the month before.
- 63
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 81
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 5
| Fund | |||
|---|---|---|---|
 SBI Contra FundSBI Mutual Fund | 4,00,73,925 | 3.29% | ₹1,483.9 Cr |
| SBI Large & Midcap FundSBI Mutual Fund | 2,41,00,000 | 2.20% | ₹892.4 Cr |
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 1,85,62,250 | 1.03% | ₹687.4 Cr |
| SBI Midcap FundSBI Mutual Fund | 1,55,98,584 | 2.48% | ₹577.6 Cr |
| SBI Balanced Advantage FundSBI Mutual Fund | 1,30,21,205 | 1.19% | ₹482.2 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 1,30,00,000 | 1.57% | ₹481.4 Cr |
 ICICI Prudential Focused FundICICI Prudential Mutual Fund | 1,24,62,450 | 2.69% | ₹461.5 Cr |
| SBI Multicap FundSBI Mutual Fund | 1,10,23,314 | 1.74% | ₹408.2 Cr |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 98,76,830 | 5.33% | ₹365.7 Cr |
| ICICI Prudential Multi Asset Allocation FundICICI Prudential Mutual Fund | 86,46,221 | 0.38% | ₹320.2 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Biocon insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade
- Others: no market trade · 2 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Biocon competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Biocon in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 LupinLUPIN | 89,263 | 16.15 | 3.98 | +28.2% | +49.5% | 27.9% | 28.2% | 0.92% |
 Glenmark PharmaceuticalsGLENMARK | 63,944 | 35.57 | 6.08 | +32.9% | +138.4% | 18.6% | 39.8% | 0.11% |
 Alkem LaboratoriesALKEM | 60,715 | 28.14 | 4.39 | +13.4% | −5.6% | 16.7% | 16.5% | 1.04% |
 Abbott IndiaABBOTINDIA | 54,218 | 33.58 | 11.36 | +6.3% | +11.2% | 35.9% | 39.6% | 2.57% |
 IPCA LaboratoriesIPCALAB | 50,254 | 38.37 | 6.23 | +10.6% | +68.2% | 17.4% | 17.6% | 0.30% |
 Gland PharmaGLAND | 48,848 | 43.27 | 4.72 | +17.6% | +46.5% | 11.6% | 12.4% | 0.68% |
 Ajanta PharmaAJANTPHARM | 41,906 | 36.93 | 9.26 | +20.2% | +22.0% | 27.3% | 27.2% | 1.79% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 41,884 | 39.21 | 18.47 | +5.8% | +12.4% | 50.6% | 56.3% | 2.31% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Biocon dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.50 a share, year to Mar 2023.
| Ex-date | Type | Per share |
|---|---|---|
| 3 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.50 |
| 4 Jul 2025 | Final | ₹0.50 |
| 5 Jul 2024 | Final | ₹0.50 |
| 7 Jul 2023 | Final | ₹1.50 |
| 30 Jun 2022 | Final | ₹0.50 |
| 18 Jul 2019 | Final | ₹0.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Biocon announcements
Oct 2026
26 Oct · Analysts
26 Oct · Board meeting
26 Oct · Updates
14 Oct · Updates
10 Oct · General Updates
1 Oct · Options to purchase securities
Biocon share price by year
Each calendar year to 2025.Biocon share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 393.90 | +7.8% | 421.60 | 302.45 |
| 2024 | 365.35 | +46.3% | 391.20 | 245.75 |
| 2023 | 249.65 | −4.7% | 276.75 | 198.70 |
| 2022 | 261.85 | −28.2% | 407.25 | 260.80 |
| 2021 | 364.65 | −21.6% | 471.75 | 321.30 |
| 2020 | 465.40 | +58.5% | 483.60 | 252.40 |
| 2019 | 293.70 | −6.6% | 335.33 | 216.15 |
| 2018 | 314.53 | +17.1% | 354.20 | 267.40 |
| 2017 | 268.65 | +69.7% | 270.43 | 148.78 |
| 2016 | 158.31 | +83.3% | 168.03 | 73.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 323.00 | 329.80 | 321.30 | 328.80 | 326.26 | 30,58,458 | 53.1% |
| 23 Oct 2026 | 330.30 | 330.90 | 318.40 | 323.50 | 323.03 | 34,71,319 | 52.6% |
| 22 Oct 2026 | 334.00 | 334.45 | 328.35 | 330.30 | 330.75 | 21,35,930 | 48.4% |
| 21 Oct 2026 | 342.00 | 344.00 | 330.75 | 335.00 | 335.10 | 24,52,266 | 53.4% |
| 19 Oct 2026 | 349.20 | 349.90 | 340.00 | 340.00 | 344.18 | 32,22,416 | 58.3% |
| 16 Oct 2026 | 352.60 | 353.00 | 348.00 | 349.20 | 349.90 | 18,76,294 | 60.3% |
| 15 Oct 2026 | 354.00 | 356.35 | 350.00 | 352.00 | 353.25 | 17,31,776 | 48.6% |
| 14 Oct 2026 | 353.00 | 353.00 | 347.00 | 350.60 | 350.93 | 33,75,381 | 63.5% |
| 13 Oct 2026 | 346.95 | 351.30 | 342.15 | 351.00 | 347.11 | 23,55,256 | 53.2% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 12 Jun 2019 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 15 Jun 2017 | Bonus | 0.3333 | Holders received 2 bonus shares for every 1 held. |
| 11 Sep 2008 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- BIOCON
- BSE code
- 532523
- ISIN
- INE376G01013
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.biocon.com
- CIN
- L24234KA1978PLC003417
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1978
- Registered office
- 20th KM Hosur Road Electronic City, Bengaluru 560100, Karnataka
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 200, BSE 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index